Nucleic Acid Nanorobotics (NANs): A Novel Platform for Oligonucleotide Therapeutics Bioanalysis

• Introducing NAN technology and its application for siRNA and ASO quantification
• Highlighting core platform capabilities, including sensitivity and robustness across complex biological matrices
• Exhibiting published evidence demonstrating accuracy, precision, and applicability to live-sample pharmacokinetic bioanalysis

Speakers:

Jurek Kozyra

Founder & Chief Executive Officer

Nanovery Ltd.